Achilles tendinopathy

Area of Science:

• Orthopedics
• Sports Medicine
• Biomedical Engineering

Background:

• Achilles tendinopathy (AT) affects 6% of the population, particularly elite athletes, causing pain and functional loss.
• Repetitive tendon overloading is a primary cause, but medication, aging, and comorbidities also contribute.
• Pathological changes include swelling, hypervascularization, and altered matrix structure driven by cellular dysfunction and inflammation.

Purpose of the Study:

• To elucidate the multifactorial etiology of Achilles tendinopathy.
• To understand the cellular and molecular underpinnings of AT.
• To identify novel therapeutic targets for improved treatment outcomes.

Main Methods:

• Review of current literature on Achilles tendinopathy pathogenesis.
• Analysis of cellular and molecular mechanisms involved in tendon degeneration.
• Exploration of emerging therapeutic strategies and precision medicine approaches.

Main Results:

• AT involves complex pathological changes including proteoglycan and fluid accumulation, and hypervascularization.
• Altered cellular function, matrix disorganization, and persistent inflammation are key drivers of tendon pathology.
• Current treatments have high failure rates, necessitating novel approaches.

Conclusions:

• Understanding the cellular and molecular basis of AT is crucial for distinguishing disease subtypes.
• Emerging therapies focus on optimizing rehabilitation and developing adjunct treatments like advanced therapy medicinal products.
• Integrating precision medicine holds promise for improving patient outcomes in Achilles tendinopathy management.